Abstract Number: 2443 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Coronary Heart Disease In Spondyloarthopathies may Be Increased Due To Higher Prevalence Of Risk Factors As Well As The Disease Itself- A Retrospective Analysis At Single VA Medical Center
Background/Purpose: An increased prevalence of cardiovascular disease (CVD) and coronary heart disease (CHD) has been reported in patients with spondyloarthritides (SpA). This study investigated the…Abstract Number: 1799 • 2013 ACR/ARHP Annual Meeting
Effect Of Certolizumab Pegol Over 48 Weeks In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Background/Purpose: Previous reports of RAPID-axSpA have demonstrated the efficacy and safety of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, in patients (pts) with axial spondyloarthritis…Abstract Number: 1506 • 2013 ACR/ARHP Annual Meeting
Total Hip Replacement Outcomes in Ankylosing Spondylitis
Background/Purpose: Historically, outcomes for total hip replacement (THR) in ankylosing spondylitis (AS) patients were poor, but contemporary outcomes are not well described. We analyzed two-year…Abstract Number: 991 • 2013 ACR/ARHP Annual Meeting
Utilization Of An Informational Needs Assessment To Develop An Education Program For Patients With Ankylosing Spondylitis (AS) and Related Axial Spondyloarthritis (SpA)
Background/Purpose: The effectiveness of education programs for patients with arthritis has been well documented. Despite this, there has been minimal investigation into patient education specifically…Abstract Number: 2776 • 2013 ACR/ARHP Annual Meeting
Ankylosing Spondylitis Is Associated With An Increased Likelihood Of Cardiovascular Disease: A Nationwide Matched Cohort Study In Primary Care
Background/Purpose: Cardiovascular disease (CVD) risk is well established in rheumatoid arthritis but less so in ankylosing spondylitis (AS). Due to a similar inflammatory profile, AS…Abstract Number: 2438 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Exercise Program in Ankylosing Spondylitis: Meta-Analysis Of Randomized Controlled Trials
Effectiveness of exercise programs in ankylosing spondylitis: meta-analysis of randomized controlled trialsVirginie Pécourneau1, Adeline Ruyssen-Witrand1, Thomas Barnetche2, Alain Cantagrel1, Arnaud Constantin1.1 Centre de Rhumatologie, HÃxpital…Abstract Number: 1802 • 2013 ACR/ARHP Annual Meeting
A Major Clinical Response To Anti-Tumor Necrosis Factor Agents Is Associated With a Reduced Development Of Fatty Changes In The Spine Of Patients With Ankylosing Spondylitis
Background/Purpose: Fatty changes (FC) on T1-weighted magnetic resonance images (MRI) have been described in the spine of patients with ankylosing spondylitis (AS). Such lesions were…Abstract Number: 1508 • 2013 ACR/ARHP Annual Meeting
How Well Are The Assessment Of Spondyloarthritis International Society (ASAS) / Outcome Measures In Rheumatology (OMERACT) Core Outcome Sets For Ankylosing Spondylitis Implemented In Randomized Clinical Trials? A Systematic Literature Review
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) has selected a core set of variables to include as standardized endpoints in clinical trials and clinical…Abstract Number: 530 • 2013 ACR/ARHP Annual Meeting
Pattern Recognition Receptor Stimulated Cytokine Expression By Spondyloarthritis Patient Macrophages
Background/Purpose: Spondyloarthritis (SpA) encompasses a group of chronic inflammatory conditions involving axial arthritis that includes ankylosing spondylitis (AS). GWAS studies in AS have implicated multiple…Abstract Number: 2697 • 2013 ACR/ARHP Annual Meeting
Identification Of Genetic and Epigenetic Alterations In Spondyloarthritis
Background/Purpose: Ankylosing spondylitis (AS) is the prototypic spondyloarthritis and affects approximately 0.2-0.5% of the human population. It is estimated that genetic risk factors contribute >90%…Abstract Number: 2440 • 2013 ACR/ARHP Annual Meeting
Is There a Role For Etoricoxib In Patients With Axial Ankylosing spondylitis Refractory To Traditional NSAID?
Background/Purpose: Anti-TNF treatment has demonstrated its effectiveness in axial ankylosing spondylitis (AS) patients with inadecuate response to traditional NSAIDs (tNSAIDs) therapy (>=2 tNSAIDs), but also aspects…Abstract Number: 1706 • 2013 ACR/ARHP Annual Meeting
Fine-Mapping Major Histocompatibility Complex Variation Associated With Ankylosing Spondylitis Susceptibility
Background/Purpose: Ankylosing spondylitis (AS) is a common, highly heritable, inflammatory arthritis. Thus far, 27 susceptibility loci have been identified in and outside the MHC in…Abstract Number: 1510 • 2013 ACR/ARHP Annual Meeting
Disease Activity In Male Smokers Has A >10-Fold Amplified Effect On Radiographic Damage In Comparison With Female NON-Smokers In Ankylosing Spondylitis
Background/Purpose: We have shown that disease activity has an effect on radiographic progression over the long-term and that gender and symptom duration are effect modifiers.…Abstract Number: 535 • 2013 ACR/ARHP Annual Meeting
Death Receptor 3 Increases Region-Specific, Osteoblast-Dependent Aberrant New Bone Formation In The Axial Skeleton Of Mice In a Spontaneous Model Of Ankylosing Enthesopathy
Background/Purpose: Clinical management of localised bone formation and joint ankylosis constitute major challenges in patients with seronegative inflammatory spondyloarthropathies (SpAs). Whether TNF receptor superfamily members,…Abstract Number: 2493 • 2013 ACR/ARHP Annual Meeting
Interleukin-17 Serum Levels Are Associated With Markers Of Systemic Inflammation In Patients With Active Ankylosing Spondylitis
Background/Purpose: There is accumulating evidence that the Th17-signaling axis, particularly interleukin-17 (IL-17), plays an important role in the pathogenesis of ankylosing spondylitis (AS). Furthermore, biologics…
- « Previous Page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- …
- 62
- Next Page »